Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.King Pharmaceuticals has begun distributing its Bicillin C-R injection for patients with penicillin-G-susceptible bacterial infections.
Subscribe to our email newsletter
Administered via deep muscular injection, Bicillin C-R is indicated for the treatment of pediatric and adult infections caused by penicillin-G-susceptible bacteria, including moderately severe to severe upper-respiratory tract infections, scarlet fever, erysipelas, streptococci-related skin and soft-tissue infections, and moderately severe pneumonia and ear infections.
“We are now manufacturing and distributing our full line of Bicillin products, which includes Bicillin C-R and Bicillin L-A,” stated Eric J. Bruce, chief technical operations officer, King Pharmaceuticals.
The company announced earlier this year that it is manufacturing and distributing Bicillin L-A (penicillin G benzathine injectable suspension) from its Michigan facility.